The Science Behind Adoptive
Cell Therapy

What is Immunotherapy for Cancer Treatment?

Activating the Immune System to Recognize and Fight Cancer

The Advantages of Immunotherapy:

  • Power to specifically target cancer
  • Possibility for long-term remissions
  • Ability to work on many types of cancer – even some that do not respond to chemotherapy or radiation

What is Adoptive Cell Therapy (ACT)?

Adoptive Cell Transfer (ACT) is a form of immunotherapy that targets tumors specifically and potently by utilizing large numbers of a patient’s own immune cells to target and destroy cancer cells. Typically, starting with a few immune cells derived from the patient’s blood, billions of cancer fighting immune cells are manufactured in a special facility, and given back to the patient, almost like a blood transfusion.

The Tactiva approach.

  • A combination of a unique class of lethal CD4-TCRs derived from hematopoietic stem cells (HSCs) and mature CD8-TCRs targeting solid tumors expressing NY-ESO-1 – NY-ESO-1 is an immunogenic cancer-testis antigen (CTA) associated with spontaneous and vaccine-induced immunity that can lead to clinical cancer responses.
  • An initial payload of CD8 cells breaks down the tumor, and the HSC-derived CD4 cleans up the remaining cells and acts as protection against the recurrence of any cancer cells expressing NY-ESO-1.

Advantages of the Tactiva approach.

  • Increased persistence
  • Increased specificity (rather than on-target toxicity)
  • Increased potency

Anticipated initiation of clinical trials: Q4 2017

Get in touch with us.

Have a question? Want to speak with someone from our team?